Incident heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) were associated with similar 1-year (29% vs 23%, p=0.15) and 5-year (61% vs 61%) mortality.
Cohort (n=664)
Yes
In a regional Australian cohort, incident heart failure admissions carry a high 5-year mortality of 61% regardless of ejection fraction, with notable underuse of echocardiography and guideline-directed medical therapies.
Absolute Event Rate: 29% vs 23%
p-value: p=0.15
AIMS: This study aims to (1) define the characteristics of patients with a first admission for heart failure (HF), stratified by type (reduced (HFrEF) vs preserved (HFpEF) ejection fraction) in a regional Australian setting; (2) compare the outcomes in terms of mortality and rehospitalisation and (3) assess adherence to the treatment guidelines. METHODS: We identified all index hospitalisations with HF to John Hunter Hospital and Tamworth Rural Referral Hospital in the Hunter New England Local Health District over a 12 months. We used the recent Australian HF guidelines to classify HFrEF and HFpEF and assess adherence to guideline-directed therapy. The primary outcome of the study was to compare short-term (1 year) and long-term all-cause mortality and the composite of all-cause hospitalisation or all-cause mortality of patients with HFrEF and HFpEF. RESULTS: There were 664 patients who had an index HF admission to John Hunter and Tamworth hospitals in 2014. The median age was 80 years, 47% were female and 22 (3%) were Aboriginal. In terms of HF type, 29% had HFrEF, 37% had HFpEF, while the remainder (34%) did not have an echocardiogram within 1 year of admission and could not be classified. The median follow-up was 3.3 years. HFrEF patients were predominantly male (64%) and in 48% the aetiology was ischaemic heart disease. The 1-year all-cause mortality was 23% in HFpEF subgroup and 29% in HFrEF subgroup (p=0.15). Five-year mortality was 61% in HFpEF and HFrEF patients. Of the HFrEF patients, only 61% were on renin-angiotensin-aldosterone blockers, 74% were on β-blockers and 39% were on aldosterone antagonist. CONCLUSION: HF patients are elderly and about evenly split between HFrEF and HFpEF. In this regional cohort, both HF types are associated with similar 1-year and 5-year mortality following incident HF hospitalisation. Echocardiography and guideline-directed therapies were underused.
Al-Omary et al. (Sun,) conducted a cohort in Incident heart failure (n=664). HFrEF vs. HFpEF was evaluated on 1-year all-cause mortality (p=0.15). Incident heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF) were associated with similar 1-year (29% vs 23%, p=0.15) and 5-year (61% vs 61%) mortality.